Having trouble accessing articles? Reset your cache.

BioLineRx reports BL-7040 ulcerative colitis data

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from 16 evaluable patients showing that oral BL-7040 for

Read the full 169 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE